QuidelOrtho Corporation announced a long‑term strategic supply agreement with Lifotronic Technology Co., Ltd., adding new immunoassay platforms and broadening its menu of assays outside the United States.
The deal gives QuidelOrtho access to multiple high‑throughput and low‑to‑mid volume immunoassay analyzer platforms and more than 25 new assays, bringing the total menu on these partner platforms to over 70 assays.
Target markets for the expanded portfolio include Europe, the Middle East, Africa, Mexico, Central America, South America, India, China, Japan and other Asia‑Pacific regions.
The partnership supports QuidelOrtho’s diversification away from COVID‑19 testing, strengthens its portfolio in core growth markets, and delivers cost‑effective, scalable solutions that can command higher margins than other business units.
"Through our collaboration with Lifotronic Technology, QuidelOrtho will rapidly introduce scalable testing solutions that further advance our long‑term innovation strategy in core growth markets. This agreement strengthens our portfolio in markets where assay breadth and cost efficiency are key requirements, while offering customers a broader and more diverse set of solutions," said Bryan Hanson, Senior Vice President of Global Clinical Laboratory and Transfusion Medicine.
"This strategic partnership with QuidelOrtho marks an important milestone in Lifotronic Technology's global expansion strategy. Going forward, we will work closely with QuidelOrtho, continuing to leverage our in‑house R&D strengths to deliver high‑value diagnostic solutions that meet real clinical needs for customers worldwide," added Liu Xiancheng, Chairman of Lifotronic Technology.
QuidelOrtho’s Q4 2025 results showed revenue of $2.73 billion, up 2.2% year‑over‑year, and adjusted EBITDA of $597 million, a 22% margin that improved 240 basis points from the prior year. The company guided 2026 revenue to $2.7 billion–$2.9 billion and adjusted EBITDA to $630 million–$670 million, but its adjusted EPS guidance of $2.00–$2.42 fell short of the consensus estimate of $2.49. The new partnership is expected to help offset the long‑term revenue decline by expanding QuidelOrtho’s international immunoassay offerings and creating a new revenue stream in high‑growth regions.
No specific market reaction to the Lifotronic agreement was reported; analyst consensus remained at a neutral hold rating.
The agreement positions QuidelOrtho to compete more effectively in global tenders, expand its revenue base, and potentially enhance margin performance by leveraging Lifotronic’s high‑throughput platforms and broad assay menu.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.